• Furmonertinib enters Hangzhou bringing upgraded medical care for its people

    On July 12, the inclusive commercial supplementary medical insurance program of “Hangzhou Shimin Bao 2021”, was officially launched, with related insurances upgraded on the 2020 basis. Proportion of reimbursement for certain expensive drug was elevated to 80% from 75%, and the category of such drugs has been extended to include 30 types of drugs, ten more than before. Furmonertinib, Allist’s first innovative drug for cancer treatment, was incorporated into Hangzhou Shimin Bao 2021’s special drug category. Furmonertinib’s entry into the city is bound to provide a higher level of medical care for local lung cancer patients.


    Furmonertinib, which got approved for market this March, is the third generation of epidermal growth factor receptor (EGFR) – tyrosine kinase inhibitor (TKI) that China self-developed with independent intellectual property right. It targets adult patients who used to experience progression of disease amid or after treatments with EGFR-TKI and diagnosed with EGFR T790M mutation-positive, locally advanced or metastatic NSCLC.


    At present, Allist is stepping up efforts to promote Furmonertinib’s entry into the categories of medical insurance programs, commercial insurance programs and local inclusive medical insurance programs so that this effective new drug becomes more widely and easily available to Chinese patients in need.